Ann W. Silk, MD, of the Rutgers Cancer Institute of New Jersey, and Katy K. Tsai, MD, of the University of California, San Francisco, who are Co-Chairs of the Clinical Immuno-Oncology Symposium, discu...
Sumanta K. Pal, MD, of the City of Hope, discusses immunotherapy as a front-line treatment for kidney cancer and the strategy of VEGF blockade with immunotherapy, which is emerging as a possible treat...
Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor BGB-290 in advanced ...
Jeffrey M. Lemons, MD, of the University of Chicago, discusses early safety and efficacy findings from a small study on pembrolizumab and multiorgan-site ablative stereotactic body radiotherapy in pat...
Roy S. Herbst, MD, PhD, of the Yale School of Medicine, summarizes a session that included discussion of the mechanisms of immunotherapies, biomarkers for activity of these agents, overcoming resistan...
James L. Gulley, MD, PhD, of the National Cancer Institute, discusses combined treatment approaches showing early evidence of clinical activity: agents such as vaccines or PARP inhibitors that can ini...
Aaron Goodman, MD, of the University of California, San Diego School of Medicine, discusses an analysis of more than 100,000 patients with cancer for CD274 (PD-L1) amplification and the implications f...
Kristen Fousek, PhD Candidate at Baylor College of Medicine, discusses her preclinical work on targeting CD19-negative relapsed B-cell acute lymphoblastic leukemia, using CAR T cells that target three...
Mary L. Disis, MD, of the University of Washington, discusses innate and adaptive immune system cells, T cells as key to mediating antitumor immunity, and the mechanisms by which cancer evades the imm...
Joaquim Bellmunt, MD, PhD, of Dana-Farber Cancer Institute, discusses refining treatment choices with new combinations and sequencing strategies.
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses integrating immune checkpoint inhibitors, improving efficacy, and reducing toxicity when treating blood cancers.